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Context:Obesity-related insulin resistance is associatedwithan increase inadipocyte size. In rodent
models, treatment with the insulin-sensitizers thiazolidinediones (TZDs) leads to the appearance
of small, insulin-sensitive adipocytes. Whether such TZD-dependent morphological changes occur
in adipose tissue of insulin-resistant patients is unclear.
Objective: The objective of the study was to study the effects of treatment with the TZD piogli-
tazone on sc adipose tissue morphology and function in insulin-resistant subjects.
Design: This was a placebo-controlled, randomized crossover study.
Setting: The study was conducted at a university medical center.
Patients: Twelve adult patientswith congenital adrenal hyperplasia (CAH) characterized by insulin
resistance were included in this study.
Intervention: After a 4-wk run-in phase, patients were treated with pioglitazone (45 mg/d) fol-
lowed by placebo, each for 16 wk or vice versa.
Main Outcome Measures: After both placebo and pioglitazone treatment, insulin sensitivity was
determined by hyperinsulinemic euglycemic clamp and abdominal sc adipose tissue was obtained
to measure adipocyte cell surface and expression of genes involved in glucose uptake and
inflammation.
Results:Pioglitazone treatment significantly improved the insulin sensitivity index (placebo: 0.35
0.16 mol/kg  min per milliunit per liter; pioglitazone 0.53 0.16 mol/kg  min per milliunit per
liter, P 0.001) and increasedmRNA expression levels of adiponectin and glucose transporter-4 in
adipose tissue. The increase in insulin sensitivity was accompanied by a significant enlargement of
the sc adipocyte cell surface (placebo: 2323  725 m2; pioglitazone 2821  885 m2, P  0.03).
Conclusions: In the human situation, treatment of insulin-resistant subjects with pioglitazone
improves insulin sensitivity, whereas at the same time, sc adipocyte cell surface increases. (J Clin
Endocrinol Metab 94: 4453–4457, 2009)
Obesity is associated with an abnormal secretion pat-tern of adipocytes and increased infiltrationofmac-
rophages into adipose tissue (1, 2). Recent studies have
shown that the increased risk for obese subjects to develop
insulin resistance and type 2 diabetes mellitus (T2DM) is
associated with increased sc abdominal adipocyte surface
(3, 4). Large adipocytes are relatively insulin insensitive
and have an increased basal lipolysis and an altered
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secretion of adipokines (5, 6). In addition, hypertrophic adi-
pocytes promote the infiltration of macrophages into adi-
pose tissue, leading to enhanced production of proinflam-
matory cytokines that contribute to the development of
insulin insensitivity (7). It has therefore been assumed that
the presence of large adipocytes may drive the develop-
ment of insulin resistance.
Thiazolidinediones (TZDs) are an insulin-sensitizing
class of pharmacological compounds widely used for
treatment of T2DM, which exhibit their insulin-sensitiz-
ing effects by decreasing visceral fat content, enhancing
insulin action, and improving glucose homeostasis (8). At
the same time, TZDs increase the sc fat depot (9). TZDs
are ligands for peroxisome proliferator-activated recep-
tor-, a nuclear transcription factor highly expressed in
adipose tissue (10). One of the adipose tissue-specific
effects of TZDs, mainly described in rodent studies, is
the stimulation of adipocyte differentiation and apo-
ptosis of large adipocytes, resulting in an increased pop-
ulation of small, more insulin-sensitive adipocytes (11).
This suggests that improvement in glucose homeostasis
by TZD treatment will be accompanied by changes in
adipocyte size.
In the present study, we investigated the effects of pio-
glitazone treatmenton insulin sensitivity, sc adipocyte sur-
face, and expression of genes involved in glucose uptake
and inflammation, in insulin-resistant subjects.
Patients and Methods
Study population
Twelve patientswith genetically characterized, classical, con-
genital adrenal hyperplasia (CAH) on a stable corticosteroid
dose were studied in a randomized crossover design. Based on
their underlying condition and chronic treatment, this group of
patients is characterized by insulin resistance (12). After a 4-wk
run-in phase, patients were randomized to treatments with pla-
cebo and pioglitazone (45 mg/d) in a blinded fashion for 16 wk
or vice versa. At the end of each treatment period, sc adipose
tissue biopsies were obtained under local anesthesia by needle
biopsies 6–10 cm lateral to the umbilicus. Samples were taken
after an overnight fast. Fasting plasma adiponectin, leptin, in-
sulin, and glucose were determined and insulin sensitivity index
(ISI) was assessed. Finally, the percentage of trunk fat was
determined.
The ethical committee of the Radboud University Nijmegen
Medical Centre approved the study protocol and the procedures
followed were in accordance with institutional guidelines. All
subjects gave written informed consent.
Adipocyte surface
Morphometry of individual fat cells was assessed in a blinded
fashion using digital image analyses as described recently (13). In
short, after biopsy, adipose tissuewas immediately fixed in para-
formaldehyde and embedded in paraffin. Subsequently paraffin
slides were stained with hematoxylin-eosin. Inasmuch our
method to measure adipocyte size requires intact cell mem-
branes, we initially optimized the thickness of our sections. Mi-
croscopic observation revealed that adipose tissue samples cut
into sections less than 8 m showed ruptured cells. To avoid
multilayered cells, we used 10-m sections for the analysis. For
each subject, surface of all fat cells in four to seven microscopic
fields of view were measured. On average, 250 fat cells were
measured per specimen (range 150–350).
RNA isolation and real-time PCR analysis
Total RNAwas extracted from sc adipose tissue usingTRIzol
reagent (Invitrogen, Carlsbad, CA). RNA concentration was de-
termined using the NanoDrop (NanoDrop Technologies, Wil-
mington,MA). cDNA synthesis was performed using the iScript
cDNA synthesis kit (Bio-RadLaboratories,Hercules, CA). Real-
time PCR was performed using Power-SYBR Green master mix
and the 7300 real-time PCR system (Applied Biosystem, War-
rington, UK). Expression of genes was normalized to 2M gene
expression levels. Primer sequences are available on request.
Insulin sensitivity and body fat distribution
Insulin sensitivity was assessed by a hyperinsulinemic eugly-
cemic clamp and expressed as glucose disposal rate and ISI es-
sentially as described previously (14). Total-body dual-energy
x-ray absorptiometry scanning was performed using a QDR
4500 densitometer (Hologic, Bedford, MA) to determine indi-
rectly the percentage of trunk fat mass by dividing the absolute
fat mass of the trunk by the total mass of the trunk.
Biochemical analyses
Glucose concentrations were measured using the oxidation
method (Glucose Analyser 2; Beckman Instruments Inc., Fuller-
ton, CA). Plasma concentrations of leptin and total adiponectin
were determined using ELISAs (R&D Systems, Minneapolis,
MN). The interassay and intraassay coefficients of variation
were 6.5 and 3.5% for total adiponectin and 4.4 and 3.2% for
leptin.
Statistical analyses
Variables are expressed as means SD. Differences in adipo-
cyte surface after placebo and pioglitazone treatment were stud-
ied using one-way univariate ANOVA. Student’s paired t test
was used to analyze statistical significance of treatment differ-
ences of other variables. Two-tailed P  0.05 was considered
significant.Tukeyhonestly significant differencepost hoc testing
was applied for multiple comparison testing. All statistics
were performed using SPSS software (version 16.0; SPSS Inc.,
Chicago, IL).
Results
Study population characteristics
Atotal of12patients [fivemen, sevenwomenaged36
9 yr; bodymass index (BMI) 26.9 4.7 kg/m2] completed
the study. Mean fasting plasma insulin, glucose, triglyc-
eride, and total cholesterol levels after placebowere 8.8
5.8mU/liter, 5.0 0.2mmol/liter, 0.96 0.3mmol/liter,
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and4.530.7mmol/liter, respectively. The cell surface of
sc adipocytes in our study population showed large vari-
ation.Whereas themean sc adipocyte surfacewas 2323
725 m2, clear interindividual differences were observed
(Fig. 1, A and B). Interestingly, adipocyte cell surface was
positively correlated with the percentage of trunk fat (r
0.73; P  0.01) and plasma leptin levels (r  0.70; P 
0.01) and negatively correlated with the ISI (r  0.60;
P 0.04) (Fig. 1C). In addition, adipocyte surface corre-
lated negatively with glucose transporter 4 (GLUT-4)
mRNA expression (r  0.65; P  0.03) and positively
with the mRNA expression level of the inflammatory
marker monocyte chemoattractant protein (MCP)-1 in
the adipose tissue (r 0.57; P 0.05) (Fig. 1D). Notice-
ably, adjustment for BMI did not significantly alter the
correlations thatwereobservedbetween thedifferent vari-
ables and adipocyte surface.
Effects of pioglitazone treatment
After16wkofpioglitazone treatment, bodyweight and
BMI had increased (by 2.0 3.3 kg and 0.7 1.1 kg/m2;
P0.06 forboth), butnodifferencewasobserved inmean
trunk fat percentage. Insulin sensitivity im-
proved significantly after pioglitazone as re-
flected by ISI (placebo: 0.35  0.16; pioglita-
zone: 0.53  0.16 mol/kg  min per milliunit
per liter), P  0.001). The ISI was based on
glucose disposal rate (placebo: 28.5  11.6
mol/kg  min;pioglitazone38.911.0mol/
kg  min,P0.001) and the insulin level at 120
min (placebo: 87.5  22.9 mU/liter; pioglita-
zone: 76.3 13.8 mU/liter, P 0.03). Subcu-
taneous adipocyte surface increased signifi-
cantly (by 497  625 m2; P  0.03) after
pioglitazone treatment: eight of 11 patients
showed larger adipocytes (Fig. 2, A andB). Pio-
glitazone had no significant effect on fasting
plasma insulin (7.9 4.1 mU/liter after piogli-
tazone), glucose (5.1  0.5 mmol/liter after
pioglitazone), adiponectin (placebo: 5.4 3.9
g/ml; pioglitazone: 6.1 4.7g/ml), and lep-
tin levels (placebo: 23.6  14.9 ng/ml; piogli-
tazone: 22.9 16.3 ng/ml). Quantitative PCR
analysis revealed increases in expression of adi-
ponectin (P  0.01) and GLUT-4 (P  0.10)
mRNA in adipose tissue after pioglitazone
treatment. MCP-1 mRNA expression ap-
peared lower after pioglitazone treatment, but
the differences were not statistically significant
(Fig. 2C). After pioglitazone treatment, the
negative correlation between sc adipocyte sur-
face and ISI was slightly weaker (r  0.58;
P  0.05), and the negative correlation be-
tween GLUT-4 and sc adipocyte surface was no longer
significant (r0.42; P 0.2). Correlations between sc
adipocyte surface and the percentage of trunk fat, plasma
leptin levels, and MCP-1 gene expression were dramati-
cally changed after pioglitazone treatment. In contrast to
placebo treatment, the percentage trunk fat and plasma
leptin levels were no longer positively correlated with sc
adipocyte surface. In addition, the positive correlation of
MCP-1 gene expression levels and adipocyte surface ob-
served after placebo treatment was lost after pioglitazone
treatment. Apparently, enlarged adipocyte surface no
longer predicts metabolic abnormalities and adipose tis-
sue functioning after pioglitazone treatment in this study
population.
Discussion
In the present study, we describe the effect of pioglitazone
on sc adipose tissue morphology, gene expression levels,
and insulin sensitivity in a group of insulin-resistant pa-
tients. Although adipocyte hypertrophy was associated
FIG. 1. Characteristics of sc adipocytes after placebo. A, Morphometry of fat cells
assessed by digital image analysis. B, Hematoxylin-eosin staining images of sc
adipose tissue of two subjects. C, Pearson correlation of mean adipocyte surface
with percentage of trunk fat, plasma leptin level, and ISI. D, Gene expression levels
of GLUT-4 and MCP-1.
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with indices of insulin resistance, pioglitazone treatment
resulted in an enlargement of sc adipocytes in parallelwith
an improvement of systemic insulin sensitivity.
The positive association between obesity-induced adi-
pocyte hypertrophy and the development of insulin resis-
tance and T2DM has been reported before (4). The de-
velopment of hypertrophic adipocytes is partly explained
by the impaired ability to differentiate new fat cells,
resulting in enlargement of existing adipocytes (15). En-
larged adipocytes are characterized by a lower insulin-
mediated glucose disposal, disturbances in lipid mobili-
zation, and secretion of higher levels of leptin compared
with smaller adipocytes (3, 16). In line with these detri-
mental effects of adipocyte hypertrophy, our data show
that after placebo enlarged sc adipocyte surface correlates
with elevated levels of circulating leptin, low insulin sen-
sitivity, and lower GLUT-4 mRNA expression, an essen-
tial glucose uptake transporter. Adipocyte surface also
positively correlates with secretion of proinflammatory
adipokines (17). In our study, the MCP-1 proinflamma-
tory gene expression positively correlated with sc adipo-
cyte surface, suggesting that enlarged adipocytes have in-
creased secretion levels of MCP-1 (17). Elevated MCP-1
levels might also be indicative of in-
creased accumulation of macrophages in
sc adipose tissue that promote the devel-
opment of insulin resistance. Altogether
our observations suggest that sc adipo-
cyte hypertrophy is indicative of unfavor-
ablemetabolic functioning of adipose tis-
sue after placebo treatment.
In agreement with previously pub-
lished studies, treatment with pioglita-
zone significantly improved insulin sen-
sitivity in our study population despite an
increase in body weight (18). Because
peroxisome proliferator-activated recep-
tor- efficiently binds TZDs and is abun-
dantly expressed in adipose tissue, pio-
glitazone is thought to primarily target
the adipose tissue in which it promotes
the development of small adipocytes
characterized by an improvement in met-
abolic function. However, evidence in
support of this mechanism of action has
mainlybeenobtained fromrodent studies
(11). The number of studies that have in-
vestigated sc adipocyte surface in re-
sponse to TZD treatment in humans is
limited and has revealed ambiguous re-
sults. So far, studies have reported no
change or an increase in the number of
small adipocytes together with an im-
provement of insulin sensitivity after TZD treatment (19,
20), although a trend toward fat cell volume increase was
also observed (21). In the present study, we observed a
clear increase in sc adipocyte surface by pioglitazone
together with an improvement of whole-body insulin
sensitivity. These divergent results may be explained by
differences in methodology. Previous studies measured
adipocyte surface using isolated adipocytes obtained after
collagenase digestion and subsequent centrifugation. This
treatment usually results in breakage of large cells, leading
to an unrepresentative sample of the original cell popula-
tionwith underestimationof large cells (22). In the present
study, immediate fixation of adipose tissue biopsies after
isolation warranted accurate estimation of adipocyte
surfaces.
Importantly, positive correlations between adipocyte
surface and plasma leptin, percentage trunk fat, and
MCP-1 gene expression levels, markers indicative of in-
sulin resistance and adipose tissue dysfunctioning, disap-
peared after pioglitazone-induced enlargement of adipo-
cytes. These findings suggest that pioglitazone-induced
adipocyte surface enlargementdoesnothaveadetrimental
FIG. 2. Characteristics of sc adipocytes after 16 wk of pioglitazone treatment. A, Individual
changes of mean sc adipocyte cell surface after pioglitazone treatment. B, Representative
hematoxylin-eosin staining images of sc adipose tissue after placebo and pioglitazone
treatment. C, Individual adipose tissue mRNA expression levels of adiponectin, GLUT-4, and
MCP-1 after both treatments. Person 4 is missing because no biopsy was taken after
pioglitazone treatment. Black dashes represent mean values.
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but a beneficial effect on adipose tissue metabolism. Hy-
pothetically the pioglitazone-induced adipocyte hypertro-
phy might result from redistribution of visceral and ec-
topic fat toward sc storage, ultimately leading to smaller
visceral, although enlarged, sc adipocytes. Because no vis-
ceral fat biopsies were taken, no data are available to sup-
port this hypothesis.
This study was performed in a group of adult patients
with CAH on stable corticosteroid treatment. These pa-
tients are characterized by insulin resistance (12) andwere
used in this study as a humanmodel for obesity-associated
insulin resistance. The advantage of this approach is that
pioglitazone treatment will not lead to changes in glucose
levels, and hence, the pure, not confounded by changes in
glycemic level, effect of the TZDon fat metabolism can be
studied. The improvement of insulin sensitivity suggests a
normal response to pioglitazone in CAH patients and af-
firms the applicability of the model. However, we cannot
exclude that other human models of insulin resistance
would show different responses.
In conclusion, our data, obtained from human adipose
tissue samples, confirm that increased sc adipocyte surface
correlates with indices of insulin resistance at the whole-
body and cellular level. Pioglitazone treatment enlarges
adipose tissue and increases adipocyte surface, whereas at
the same time improving the systemic insulin sensitivity.
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